• English
  • 简体中文
Login Register
Current Location: Home > Drug Registration and Acceptance subscription Help
-
-
-
Visualized Analysis Export Evaluation Conclusion Evaluation Progress
Acceptance No. Drug Name Active Ingredient Dosage Form Classification Submission Acceptance Date Manufacturers Manufacturers Review Status Status Date View
JXSS2101025 甘精胰岛素利司那肽注射液2:1 insulin glargine;lixisenatide Injection Biological Products(3.1) Import Drug Application 2021-09-30 Sanofi-Aventis Groupe;Sanofi-Aventis Deutschland GmbH;Sanofi (China) Investment Co Ltd view
JYSB2400174 甘精胰岛素利司那肽注射液(Ⅱ) insulin glargine;lixisenatide Injection Biological Products Supplementary Application 2024-08-09 Sanofi-Aventis Deutschland GmbH;Sanofi Winthrop Industrie view
AS20000032 甘精胰岛素注射液 insulin glargine Injection Biological Products New Drug Application 2000-10-31 安万特(中国)投资有限公司 Sanofi (China) Investment Co Ltd Approval Completed-Pending Certificated view
JXSL2101132 甘精胰岛素利司那肽注射液2:1 insulin glargine;lixisenatide Injection Biological Products(3.1) Import Drug Application 2021-11-17 Sanofi-Aventis Groupe;Sanofi (China) Investment Co Ltd view
CXSL2500306 甘精胰岛素注射液 insulin glargine Injection Biological Products(3.3) New Drug Application 2025-04-16 Yifan Pharmaceutical (Shanghai) Co Ltd view
CYSB2300082 甘精胰岛素注射液 insulin glargine Injection Biological Products(3.4) Supplementary Application 2023-04-13 Shandong New Time Pharmaceutical Co Ltd view
JYSB2400242 甘精胰岛素注射液 insulin glargine Injection Biological Products Supplementary Application 2024-11-23 Sanofi-Aventis Deutschland GmbH view
CYSB2200118 甘精胰岛素注射液 insulin glargine Injection Biological Products Supplementary Application 2022-05-18 Tonghua Dongbao Pharmaceutical Co Ltd view
CYSB2400041 甘精胰岛素注射液 insulin glargine Injection Biological Products Supplementary Application 2024-02-09 Gan & Lee Pharmaceuticals view
CYSB2101083 甘精胰岛素注射液 insulin glargine Injection Biological Products Supplementary Application 2021-06-03 Sanofi (Beijing) Pharmaceuticals Co Ltd view
JXSS2200043 甘精胰岛素注射液 insulin glargine Injection Biological Products(3.3) Import Drug Application 2022-12-27 Lilly France;Eli Lilly Nederland BV;Lilly Suzhou Pharmaceutical Co Ltd view
JYSB2400099 甘精胰岛素利司那肽注射液(Ⅰ) insulin glargine;lixisenatide Injection Biological Products Supplementary Application 2024-05-06 Sanofi KK;Sanofi-Aventis Deutschland GmbH view
CYSB2101250 甘精胰岛素注射液 insulin glargine Injection Biological Products Supplementary Application 2021-11-03 Sanofi (Beijing) Pharmaceuticals Co Ltd view
JYSB2400173 甘精胰岛素利司那肽注射液(Ⅰ) insulin glargine;lixisenatide Injection Biological Products Supplementary Application 2024-08-09 Sanofi KK;Sanofi-Aventis Deutschland GmbH view
CYSB2200127 甘精胰岛素注射液 insulin glargine Injection Biological Products(3.3) Supplementary Application 2022-06-02 Yichang HEC Changjiang Pharmaceutical Co Ltd view
CYSB2300079 甘精胰岛素注射液 insulin glargine Injection Biological Products Supplementary Application 2023-04-05 Gan & Lee Pharmaceuticals view
JYSB2101113 甘精胰岛素注射液 insulin glargine Injection Biological Products Supplementary Application 2021-08-26 Sanofi-Aventis Deutschland GmbH view
CYSB2300211 甘精胰岛素注射液 insulin glargine Injection Biological Products Supplementary Application 2023-11-22 Sanofi (Beijing) Pharmaceuticals Co Ltd view
CYSB2101082 甘精胰岛素注射液 insulin glargine Injection Biological Products Supplementary Application 2021-06-03 Sanofi (Beijing) Pharmaceuticals Co Ltd view
CYSB2400236 甘精胰岛素注射液 insulin glargine Injection Biological Products Supplementary Application 2024-09-13 Zhuhai United Laboratories Co Ltd view